‘Mix and Match’ vaccination: Is dengue next?

[1]  D. Montefiori,et al.  Homologous and Heterologous Covid-19 Booster Vaccinations , 2022, The New England journal of medicine.

[2]  V. Libri,et al.  Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial , 2021, The Lancet.

[3]  Scott M Elliott,et al.  Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial , 2021, The Lancet.

[4]  Vianney Tricou,et al.  Three-year Efficacy and Safety of Takeda’s Dengue Vaccine Candidate (TAK-003) , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  A. Nordström,et al.  Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study , 2021, The Lancet Regional Health - Europe.

[6]  J. Izopet,et al.  Heterologous ChAdOx1-S/BNT162b2 vaccination: neutralizing antibody response to SARS-CoV-2 , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  F. Cosset,et al.  Immunogenicity and efficacy of          heterologous ChAdOx1–BNT162b2 vaccination , 2021, Nature.

[8]  V. Libri,et al.  Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial , 2021, The Lancet.

[9]  C. von Kalle,et al.  Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study , 2021, The Lancet Respiratory Medicine.

[10]  B. Gärtner,et al.  Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination , 2021, Nature Medicine.

[11]  K. Überla,et al.  Heterologous prime–boost vaccination with ChAdOx1 nCoV-19 and BNT162b2 , 2021, The Lancet Infectious Diseases.

[12]  Lindsay N. Carpp,et al.  Analysis of Neutralizing Antibodies as a Correlate of Instantaneous Risk of Hospitalized Dengue in Placebo Recipients of Dengue Vaccine Efficacy Trials. , 2021, The Journal of infectious diseases.

[13]  R. Baric,et al.  Dengue vaccine breakthrough infections reveal properties of neutralizing antibodies linked to protection. , 2021, The Journal of clinical investigation.

[14]  Andreas Greinacher,et al.  Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination , 2021, The New England journal of medicine.

[15]  C. Diazgranados,et al.  Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  Zhilin Zeng,et al.  Global, regional, and national dengue burden from 1990 to 2017: A systematic analysis based on the global burden of disease study 2017 , 2021, EClinicalMedicine.

[17]  A. Pollard,et al.  A guide to vaccinology: from basic principles to new developments , 2020, Nature reviews. Immunology.

[18]  Vianney Tricou,et al.  Efficacy of a Dengue Vaccine Candidate (TAK-003) in Healthy Children and Adolescents 2 Years after Vaccination , 2020, The Journal of infectious diseases.

[19]  R. Baric,et al.  Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003) , 2020, bioRxiv.

[20]  Gregory D. Gromowski,et al.  Immunogenicity of a Live-Attenuated Dengue Vaccine Using a Heterologous Prime-Boost Strategy in a Phase I Randomized Clinical Trial. , 2020, The Journal of infectious diseases.

[21]  A. Wilder-Smith.  Dengue vaccine development by the year 2020: challenges and prospects , 2020, Current Opinion in Virology.

[22]  Jianzhu Chen,et al.  Sequential immunization induces strong and broad immunity against all four dengue virus serotypes , 2020, npj Vaccines.

[23]  J. Mascola,et al.  Distinct neutralizing antibody correlates of protection among related Zika virus vaccines identify a role for antibody quality , 2020, Science Translational Medicine.

[24]  Alejandro Macias,et al.  Combine dengue vaccines to optimize effectiveness. , 2020, Vaccine.

[25]  K. Pierce,et al.  Immunogenicity and Safety of a Tetravalent Recombinant Subunit Dengue Vaccine in Adults Previously Vaccinated with a Live Attenuated Tetravalent Dengue Vaccine: Results of a Phase-I Randomized Clinical Trial. , 2020, The American journal of tropical medicine and hygiene.

[26]  A. Sette,et al.  Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial. , 2020, The Lancet. Infectious diseases.

[27]  E. Moreira,et al.  Efficacy of a tetravalent dengue vaccine in healthy children aged 4–16 years: a randomised, placebo-controlled, phase 3 trial , 2020, The Lancet.

[28]  G. Pantaleo,et al.  Heterologous Combination of VSV-GP and NYVAC Vectors Expressing HIV-1 Trimeric gp145 Env as Vaccination Strategy to Induce Balanced B and T Cell Immune Responses , 2019, Front. Immunol..

[29]  S. Quake,et al.  Broadly neutralizing human antibodies against dengue virus identified by single B cell transcriptomics , 2019, eLife.

[30]  J. Kublin,et al.  Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial , 2019, The lancet. HIV.

[31]  A. Sette,et al.  Human T Cell Response to Dengue Virus Infection , 2019, Front. Immunol..

[32]  L. Lazo,et al.  Can Complementary Prime-Boost Immunization Strategies Be an Alternative and Promising Vaccine Approach Against Dengue Virus? , 2019, Front. Immunol..

[33]  Chaim A. Schramm,et al.  Activation Dynamics and Immunoglobulin Evolution of Pre-existing and Newly Generated Human Memory B cell Responses to Influenza Hemagglutinin. , 2019, Immunity.

[34]  Stephen J. Thomas,et al.  Assessing the Diversity and Stability of Cellular Immunity Generated in Response to the Candidate Live-Attenuated Dengue Virus Vaccine TAK-003 , 2019, Front. Immunol..

[35]  M. Guzmán,et al.  A heterologous prime-boost strategy for immunization against Dengue virus combining the Tetra DIIIC subunit vaccine candidate with the TV005 live-attenuated tetravalent vaccine. , 2019, The Journal of general virology.

[36]  G. Ebel,et al.  Dengue type 1 viruses circulating in humans are highly infectious and poorly neutralized by human antibodies , 2018, Proceedings of the National Academy of Sciences.

[37]  J. Kublin,et al.  Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial , 2018, The lancet. HIV.

[38]  T. Westling,et al.  Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy , 2018, The New England journal of medicine.

[39]  Lindsay N. Carpp,et al.  Neutralizing Antibody Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin America , 2018, The Journal of infectious diseases.

[40]  M. Halloran,et al.  Antibody-dependent enhancement of severe dengue disease in humans , 2017, Science.

[41]  Vianney Tricou,et al.  Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study. , 2017, The Lancet. Infectious diseases.

[42]  K. Subbarao,et al.  In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination , 2017, PLoS neglected tropical diseases.

[43]  B. Guy,et al.  Dissecting Antibodies Induced by a Chimeric Yellow Fever–Dengue, Live-Attenuated, Tetravalent Dengue Vaccine (CYD-TDV) in Naive and Dengue-Exposed Individuals , 2016, The Journal of infectious diseases.

[44]  K. Subbarao,et al.  A 12-Month-Interval Dosing Study in Adults Indicates That a Single Dose of the National Institute of Allergy and Infectious Diseases Tetravalent Dengue Vaccine Induces a Robust Neutralizing Antibody Response. , 2016, The Journal of infectious diseases.

[45]  A. Bolhassani,et al.  Prime-boost vaccine strategy against viral infections: Mechanisms and benefits. , 2016, Vaccine.

[46]  D. Stinchcomb,et al.  Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: A Phase 1b randomized study. , 2015, Vaccine.

[47]  K. Subbarao,et al.  Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults. , 2015, The Journal of infectious diseases.

[48]  S. Whitehead,et al.  Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies , 2015, Journal of Virology.

[49]  P. Desprès,et al.  Recognition determinants of broadly neutralizing human antibodies against dengue viruses , 2015, Nature.

[50]  Mehran Kardar,et al.  Manipulating the selection forces during affinity maturation to generate cross-reactive HIV antibodies , 2015, Cell.

[51]  M. R. Capeding,et al.  Immunogenicity and safety of a tetravalent dengue vaccine during a five-year follow-up period , 2015 .

[52]  H. Liao,et al.  HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial. , 2014, The Journal of clinical investigation.

[53]  M. Boaz,et al.  Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA. , 2013, Vaccine.

[54]  T. Scott,et al.  Reduced risk of disease during postsecondary dengue virus infections. , 2013, The Journal of infectious diseases.

[55]  Ravi V. Kolla,et al.  Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells , 2013, Proceedings of the National Academy of Sciences.

[56]  J. Lang,et al.  Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans. , 2011, The American journal of tropical medicine and hygiene.

[57]  S. Eo,et al.  Distinct Humoral and Cellular Immunity Induced by Alternating Prime-boost Vaccination Using Plasmid DNA and Live Viral Vector Vaccines Expressing the E Protein of Dengue Virus Type 2 , 2011, Immune network.

[58]  B. Murphy,et al.  Heterotypic dengue infection with live attenuated monotypic dengue virus vaccines: implications for vaccination of populations in areas where dengue is endemic. , 2011, The Journal of infectious diseases.

[59]  J. García-Machorro,et al.  A plasmid encoding parts of the dengue virus E and NS1 proteins induces an immune response in a mouse model , 2010, Archives of Virology.

[60]  J. Lang,et al.  A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. , 2010, The Journal of infectious diseases.

[61]  J. Lynch,et al.  Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy. , 2010, Virology.

[62]  Jerome H. Kim,et al.  Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. , 2009, The New England journal of medicine.

[63]  B. Guy,et al.  Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects. , 2008, Vaccine.

[64]  Richard G Jarman,et al.  Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences. , 2007, The American journal of tropical medicine and hygiene.

[65]  K. Porter,et al.  A Heterologous DNA Prime-Venezuelan Equine Encephalitis Virus Replicon Particle Boost Dengue Vaccine Regimen Affords Complete Protection from Virus Challenge in Cynomolgus Macaques , 2007, Journal of Virology.

[66]  D. Vaughn,et al.  Characterization of Antibody Responses to Combinations of a Dengue Virus Type 2 DNA Vaccine and Two Dengue Virus Type 2 Protein Vaccines in Rhesus Macaques , 2006, Journal of Virology.

[67]  J. García-Cordero,et al.  DNA priming E and NS1 constructs--homologous proteins boosting immunization strategy to improve immune response against dengue in mice. , 2005, Viral immunology.

[68]  T. Kochel,et al.  Characterization of antibody responses to combinations of a dengue-2 DNA and dengue-2 recombinant subunit vaccine. , 2001, The American journal of tropical medicine and hygiene.

[69]  S. Halstead.  In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody. , 1979, The Journal of infectious diseases.